Investor Relations

Data as of Mar 25, 2019 4:20 PM EDT

PRESS RELEASES

March 13, 2019

Summary Toggle Positive FDA Meeting Outlines Path Ahead for Akari Therapeutics’s Coversin in Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA)

HSCT-TMA trial in pediatric patients expected to start Q4 2019 following recent FDA feedback NEW YORK and LONDON , March 13, 2019 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory
November 30, 2018

Summary Toggle Akari Therapeutics Announces New Data Highlighting Differentiation of Drug Candidate Coversin

Planned introduction of patient-friendly pen auto-injector in 2019 designed to increase comfort and convenience of treatment across the entire Akari subcutaneous program Second eculizumab-resistant patient with paroxysmal nocturnal haemoglobinuria (PNH) successfully treated with Coversin for more
November 15, 2018

Summary Toggle Akari Announces Coversin Data to be Presented at 2018 Complement-Based Drug Development Summit

Highlights potential role of both complement and leukotriene pathways in a therapeutic mouse model of rheumatoid arthritis (RA) NEW YORK and LONDON , Nov. 15, 2018 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), a biopharmaceutical company focused on innovative therapeutics to treat

Company Presentation – October 2018

October 1, 2018

Company Presentation – October 2018 380.6 KB
EHA 2018 Poster

June 15, 2018

EHA 2018 Poster 467.9 KB
ARVO 2018 Poster

May 16, 2018

ARVO 2018 Poster 378.7 KB